Lan Lan, Wang Xinyu, Zhang Simeng, Zeng Dan, Mo Limin, Feng Qiao, Li Jun, Zhu Chunjiang
Genetics and Precision Medicine Laboratory, Affiliated Hospital of Guilin Medical University, Guilin, China.
Ann Med. 2025 Dec;57(1):2530690. doi: 10.1080/07853890.2025.2530690. Epub 2025 Jul 11.
MicroRNAs (miRNAs) have emerged as regulators of pathogenesis in hematopoiesis by targeting post-transcription mRNA regulation. However, the involvement of miRNAs in hemoglobin H-Constant Spring (HbH-CS) disease remains unclear. The present study analyzed miRNAs differential expression profile between patients with HbH-CS disease and healthy subjects by Arraystar Human small RNA Microarray.
The differential expression profiles of miRNAs between HbH-CS patients and healthy individuals were analyzed using Arraystar human small RNA microarrays. Quantitative real-time PCR and Western blot were used to detect the mRNA and protein expression. Bioinformatics methods were used to predict the target genes of miRNAs, and the regulatory relationship between miRNAs and target genes was verified by dual-luciferase reporter assay. Cell apoptosis was detected by flow cytometry, and cell proliferative capacity was detected by CC K-8 assay.
MiR-223-3p was significantly down-regulated in HbH-CS patients. Dual-luciferase reporter assay demonstrated that miR-223-3p specifically targeted TGFBR3. The experiments showed that miR-223-3p inversely regulated the expression levels of TGFBR3, Smad2/3, and P-Smad2. We found that overexpression of miR-223-3p in K562 cells significantly promoted cellular proliferation and inhibited cellular apoptosis by suppressing expression of TGFBR3, Smad2/3, and P-Smad2. Moreover, up-regulation of miR-223-3p in induced K562 cells increased the expression levels of hemoglobin and mean corpuscular hemoglobin.
In conclusion, this study indicated that the interaction between miR-223-3p and TGFBR3/Smad signaling pathway might affect erythropoiesis in HbH-CS disease, which can provide more information for the treatment of patients.
微小RNA(miRNA)已成为通过靶向转录后mRNA调控来调节造血发病机制的因子。然而,miRNA在血红蛋白H-Constant Spring(HbH-CS)病中的作用仍不清楚。本研究通过Arraystar人类小RNA芯片分析了HbH-CS病患者与健康受试者之间miRNA的差异表达谱。
使用Arraystar人类小RNA芯片分析HbH-CS患者与健康个体之间miRNA的差异表达谱。采用定量实时PCR和蛋白质印迹法检测mRNA和蛋白质表达。运用生物信息学方法预测miRNA的靶基因,并通过双荧光素酶报告基因检测验证miRNA与靶基因之间的调控关系。通过流式细胞术检测细胞凋亡,采用CCK-8法检测细胞增殖能力。
miR-223-3p在HbH-CS患者中显著下调。双荧光素酶报告基因检测表明miR-223-3p特异性靶向TGFBR3。实验表明,miR-223-3p反向调节TGFBR3、Smad2/3和P-Smad2的表达水平。我们发现,在K562细胞中过表达miR-223-3p可通过抑制TGFBR3、Smad2/3和P-Smad2的表达显著促进细胞增殖并抑制细胞凋亡。此外,在诱导的K562细胞中上调miR-223-3p可增加血红蛋白和平均红细胞血红蛋白的表达水平。
总之,本研究表明miR-223-3p与TGFBR3/Smad信号通路之间的相互作用可能影响HbH-CS病中的红细胞生成,这可为患者的治疗提供更多信息。